Please use this identifier to cite or link to this item:
|Statistics||SHARE CORE MendeleyBASE||
|Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL|
Fructose-1,6-biphosphate in rat intestinal preconditioning: involvement of nitric oxide
|Authors:||Solà, Anna M. ; Roselló-Catafau, Joan ; Gelpí, Emili ; Hotter, Georgina|
Glyceraldehyde- 3-phosphate dehydrogenase
|Publisher:||BMJ Publishing Group|
|Citation:||Gut. 2001 February; 48(2): 168–175.|
|Abstract:||[BACKGROUND AND AIMS] Inhibition of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) by nitric oxide (NO) in intestinal preconditioning could modify the rate of formation of glycolytic intermediates. Fructose-1,6-biphosphate (F16BP) is a glycolytic intermediate that protects tissue from ischaemia/reperfusion injury. We evaluated if F16BP may be endogenously accumulated as a consequence of GAPDH inhibition by NO during intestinal preconditioning in rats.|
[METHODS] We assessed: (1) effect of preconditioning on F16BP content; (2) effect of NO on GAPDH activity before and during sustained ischaemia; and (3) protective effect of F16BP in control, ischaemic, and preconditioned animals with or without administration of N-nitro-L-arginine methyl ester (L-NAME), NO donor, or F16BP.
[RESULTS] Preconditioned rats showed a significant transient decrease in GAPDH activity and also maintained basal F16BP levels longer than ischaemic rats. L-NAME administration to preconditioned rats reversed these effects. F16BP administration to ischaemic rats decreased protein release in the perfusate. Administration of F16BP to L-NAME treated rats attenuated the harmful effect of L-NAME.
[CONCLUSIONS] Our study indicates that F16BP may be endogenously accumulated in preconditioned rats as a consequence of inhibition of GAPDH by NO, and this may contribute to the protection observed in intestinal preconditioning.
|Publisher version (URL):||http://dx.doi.org/10.1136/gut.48.2.168|
|Appears in Collections:||(IIBB) Artículos|
Files in This Item:
|fructose.pdf||Text file||151,04 kB||Adobe PDF|
|fructose_f1.jpg||Figure 1.- Intestinal fructose-1,6-biphosphate (F16BP) levels during the different ischaemic periods (0, 2, 30, or 90 minutes) in the control.||73,74 kB||JPEG|
|fructose_f2.jpg||Figure 2.- Intestinal glucose levels during the different ischaemic periods (0, 2, 30, or 90 minutes) in the control.||47,05 kB||JPEG|
|fructose_f3.jpg||Figure 3.- GAPDH activity (U/mg protein) in the intestine during the different ischaemic periods (0, 2, 30, or 90 minutes) in the control.||73,04 kB||JPEG|
|fructose_f4.jpg||Figure 4.- Nitrate and nitrite tissue production in the intestine in the following groups: control, control with previous administration of L-NAME (C+NAME), preconditioning.||45,75 kB||JPEG|
|fructose_f5.jpg||Figure 5.- Profiles of protein release during the different ischaemic (0, 2, 30, and 90 minutes) and reperfusion.||53,72 kB||JPEG|
|fructose_f6.jpg||Figure 6.- Intestinal fructose-1,6-biphosphate (F16BP) levels incorporated in the intestine.||19,54 kB||JPEG|